DGAP-News

MOLOGEN AG: Recruitment goal achieved for the pivotal IMPALA study with lefitolimod in colorectal cancer patients

DGAP-News: MOLOGEN AG / Key word(s): Study MOLOGEN AG: Recruitment goal achieved for the pivotal IMPALA study with lefitolimod in colorectal cancer patients 15.05.2017 / 08:40 The issuer is solely responsible for the content of this announcement. PRESS RELEASE N 11 / 2017 of 15/05/2017

MOLOGEN AG: Recruitment goal achieved for the pivotal IMPALA study with lefitolimod in colorectal cancer patients

Berlin, 15 May 2017 - The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) has achieved the recruitment goal with the inclusion of currently 540 patients for the pivotal IMPALA study in metastatic colorectal cancer "mCRC". The aim of this study is to show that a switch maintenance therapy with the immunotherapeutic agent lefitolimod can lead to a prolongation of overall survival in patients with mCRC. With the finalization of recruitment, the company reached the next important milestone in the clinical study program of its lead product lefitolimod.

"We are pleased that the enrollment for IMPALA has been completed and that treatment with lefitolimod is so far well tolerated", said Dr. Matthias Baumann, Chief Medical Officer of MOLOGEN AG. "This is an important milestone for us as the pivotal IMPALA study is by far the largest study for us to date. We look forward to the study results in this high medical need indication, which will be available, once sufficient survival data have been collected. This is currently expected in 2019, which of course depends on the actual overall survival rates.

Approximately 540 patients from more than 120 centers in eight European countries, including the five most important European pharmaceutical markets, participate in the study. The study will be evaluated once a certain number of deaths (events) have occurred, which is currently estimated to be reached around two years after completion of patient enrollment. MOLOGEN is continuously and closely monitoring the events and the corresponding timeline for the results.